Moberg Derma

November 2012

BUYER

Moberg Pharma is a Swedish pharmaceutical company that commercializes proprietary, acquired and licensed products in the global market. Initially, the company specializes in the treatment of skin diseases but is now widening its scope. Moberg Pharma markets OTC brands in the U.S. and sells through distributors in more than 40 countries. Moberg Pharma has sales of SEK 157 million.

TARGET

Alterna is a US pharmaceutical company within dermatology and topical pain treatment. The company’s primary products Kerasal® and JointFlex® are brands with established positions in the US. Moberg Pharma has been engaged in a distribution partnership with Alterna since 2011. Alterna has sales of USD 10.3 million.

SELLER

Altaris Private Equity, a US based private equity fund specialising in [life science] investments.

TRANSACTION

Acquisition of Alterna LLC, Moberg Pharma’s disitrbutor in North American and 50% owner of Moberg Pharma’s most important drug Emtrix/Nalox.